Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 33
-2.37%-4.19%+39.49%+63.21% 63.77B
-2.87%+0.49%+10.45%+69.18% 56.37B
+0.62%+2.11%+20.22%+102.56% 54.62B
-3.57%-5.05%+21.46%+36.40% 44.06B
-1.99%-1.71%+16.89%+100.24% 42.11B
-1.15%+3.34%+220.31%+798.53% 41B
-5.47%+24.76%+98.34%+87.34% 34.92B
+0.21%-1.23%+14.81%+47.35% 32.82B
-2.79%+18.45%-40.64%+342.02% 24.7B
Average -1.92%+7.73%+44.59%+182.98% 43.82B
Weighted average by Cap. -2.06%+5.64%+45.18%+165.21%
Logo ARYx Therapeutics, Inc.
ARYx Therapeutics, Inc. is a United States-based pharmaceutical Company. The Company is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. It is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.
Employees
56
  1. Stock Market
  2. Stocks
  3. ARYX Stock